Tech Company Financing Transactions
Vivatides Therapeutics Funding Round
On 4/13/2026, Vivatides Therapeutics received $54 million in Series A financing from Qiming Venture Partners USA, HighLight Capital and TF Capital.
Transaction Overview
Company Name
Announced On
4/13/2026
Transaction Type
Venture Equity
Amount
$54,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to further enhance preclinical optimization and IND-enabling studies, expand its R&D and management teams, and continue to accelerate the development of its platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Woburn, MA 01813
USA
Woburn, MA 01813
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Vivatides Therapeutics Inc. is a biotechnology startup specializing in next-generation extrahepatic RNA therapeutics. Founded in 2025, the company is developing a platform designed to deliver RNA-based medicines--specifically siRNA and antisense oligonucleotides (ASO)--to tissues and organs beyond the liver, which has historically been a major barrier in RNA medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Keming Zhou
Browse more venture capital transactions:
Prev: 4/10/2026: Elorian venture capital transaction
Next: 4/13/2026: Aeluma venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs